MELANOMA: tratamiento de primera línea - page 35

Overall Survival Metastatic Melanoma<br />1-year OS Phase III Studies

Adapted from Georgina Long presented at ASCO 2016

40%

55%

44%

70% Nivo

57’7% Nivo (Ph III)

C+V 3y = 37.4%

D+T 3y = 45%

C+V 4y (pre-treated) = 35.9%,

COMBINACIONES: EL FUTURO?

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,25,26,27,28,29,30,31,32,33,34 36,37